Can You Take Meloxicam with CYCLOBENZAPRINE HYDROCHLORIDE?
Understanding the major interaction between Meloxicam (CIPLA MELOXICAM 7.5) and CYCLOBENZAPRINE HYDROCHLORIDE (CYCLOBENZAPRINE HYDROCHLORIDE) for claims professionals, support workers, and care managers.
Taking Meloxicam (CIPLA MELOXICAM 7.5) with CYCLOBENZAPRINE HYDROCHLORIDE (CYCLOBENZAPRINE HYDROCHLORIDE) is a major drug interaction that should be avoided. Excessive sedation, respiratory depression, falls. Additive CNS depression. Both classes cause sedation and respiratory depression through complementary pathways.
Key Takeaways
- Interaction severity: Major
- Risk: Excessive sedation, respiratory depression, falls.
- Mechanism: Additive CNS depression. Both classes cause sedation and respiratory depression through complementary pathways.
- Meloxicam: S4 in Australia, low risk
- CYCLOBENZAPRINE HYDROCHLORIDE: S4 in Australia, low risk
- Claims action: Flag for immediate prescriber review. Document intervention in claim file.
Meloxicam vs CYCLOBENZAPRINE HYDROCHLORIDE at a Glance
| Property | Meloxicam | CYCLOBENZAPRINE HYDROCHLORIDE |
|---|---|---|
| Brand names | CIPLA MELOXICAM 7.5, MELOBIC, APX-Meloxicam | CYCLOBENZAPRINE HYDROCHLORIDE |
| Drug class | opioid | muscle relaxant |
| Risk level | low | low |
| TGA Schedule (AU) | S4 | S4 |
Why Is This Combination Dangerous?
Additive CNS depression. Both classes cause sedation and respiratory depression through complementary pathways.
Regulatory Guidance by Jurisdiction
Australia TGA / SIRA / WorkSafe
The TGA and Australian Medicines Handbook classify this as a major drug interaction requiring immediate intervention.
United Kingdom NICE / MHRA / FPM
UK clinical guidelines recommend caution with this combination. For personal injury claims, the prescribing rationale should be documented and reviewed against NICE and FPM guidance.
United States FDA / CDC / State WC
The CDC and FDA recommend monitoring concurrent CNS depressant use. State workers compensation formularies may restrict or require prior authorization for this combination.
What Claims Professionals Should Do
- Flag immediately as a high-risk prescribing pattern in the claim file
- Request urgent prescriber review with documented clinical justification for the combination
- Consider an independent medical examination if the prescriber cannot provide adequate justification
- Assess work capacity impact as the combination significantly increases sedation and impairment risk
- Document all interventions for audit trail and compliance purposes
- Check Reasonable and Necessary status for both medications against the compensable injury
Need to assess this medication across your caseload?
Check all interactions for Meloxicam and CYCLOBENZAPRINE HYDROCHLORIDE across your claimant's full medication list.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Related Resources
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.